William G. Wierda, MD, PhD | Authors


Reviewing Key Points from the Phase III MURANO Trial in CLL

May 11, 2019

William G. Wierda, MD, PhD, discusses the take home message from the phase III MURANO trial that identified venetoclax plus rituximab as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia.